Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
Ryerson, Lana Zhovtis, Foley, John, Chang, Ih, Kister, Ilya, Cutter, Gary, Metzger, Ryan R., Goldberg, Judith D., Li, Xiaochun, Riddle, Evan, Smirnakis, Karen, Kasliwal, Rachna, Ren, Zheng, Hotermans,Journal:
Neurology
DOI:
10.1212/WNL.0000000000008243
Date:
September, 2019
Fichier:
PDF, 840 KB
2019
File converter
Plus de résultats de recherche
More benefits 
